# Nisha Marathe

> Nisha Marathe is a Series A investor at Roche Venture Fund backing Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund)
- Location: San Francisco, United States
- Total investments: 2
- Last investment: May 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/nisha-marathe-b0461614/

Nisha Marathe is a Series A investor at Roche Venture Fund in San Francisco focused on Health Care and Biotechnology. Nisha Marathe

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Biopharma | 1 | 50% |
| Therapeutics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Soteria Biotherapeutics | Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity,reduced side effects and higher dosing. | $42M | Series A | May 17, 2021 |  |
| IDEAYA Biosciences | IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, locatedin South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery. | $94M | Series B | Mar 15, 2018 |  |

2 of 2 investments shown.

## Co-investors
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 2 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 1 deal together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together

## About Roche Venture Fund

VC Fund · Basel, Switzerland

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

5 contacts available at Roche Venture Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Carole Nuechterlein | Head of Roche Venture Fund | https://shizune.co/investors/profile/carole-nuechterlein |
| Monique Schiersing | Investment Director | https://shizune.co/investors/profile/monique-schiersing |
| Simon Greenwood | Investment Director | https://shizune.co/investors/profile/simon-greenwood |
| Simon Meier | Investment Director | https://shizune.co/investors/profile/simon-meier |
| Nisha Marathe | Investment Manager | https://shizune.co/investors/profile/nisha-marathe |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Nisha Marathe invest in?

Nisha Marathe invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Nisha Marathe last invest?

The most recent investment recorded for Nisha Marathe closed in May 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co